CompletedPhase 3

Trazodone for Sleep Disorders in Alzheimer's Disease

Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study

Lead sponsor

Brasilia University Hospital

Asset

Trazodone

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoint

•Nighttime Total Sleep Time

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01142258

Org study IDTZD-001

Timeline

Milestones

Study start2010-03 (month precision)

Study first posted2010-06-11estimated

Primary completion2012-04actual (month precision)

Study completion2012-08actual (month precision)

Last update posted2012-10-15estimated

Assets

Drug assets

Trazodone

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Fifty-five years of age or older;

•Diagnosis of probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association criteria;

•Hachinski Ischemia Scale score less than 5

•Mini-Mental State Examination score of O to 26

•Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week;

•For-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale;

•Sleep disturbance observed was not present before the diagnosis of AD;

•Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms;

•Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infarct in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal;

•Stable medications for 4 weeks prior to the screening visit;

•Having a mobile upper extremity to which to attach an actigraph;

•Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principal caregiver for the 3-week protocol;

•Ability to ingest oral medication and participate in all scheduled evaluations

Exclusion criteria

•Sleep disturbance associated with an acute illness, delirium or psychiatric disease;

•Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness

•Severe agitation;

•Unstable medical condition;

•Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit;

•Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of the protocol;

•Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 PM for the duration of the protocol;

•Prior use of trazodone for the treatment of sleep disturbances;

•Caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Behavior / neuropsychiatric

Global cognition

Other (unclassified)

Function / daily living